Clearside Biomedical (CLSD) 10-Q 10 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 06, 2020
Cover [Abstract]
Entity Registrant Name	Clearside Biomedical, Inc.
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	CLSD
Document Type	10-Q
Entity Central Index Key	0001539029
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Interactive Data Current	Yes
Document Transition Report	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Entity Common Stock, Shares Outstanding		48,353,952
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity File Number	001-37783
Entity Tax Identification Number	45-2437375
Entity Address, Address Line One	900 North Point Parkway
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30005
City Area Code	678
Local Phone Number	270-3631

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 14,839	$ 22,595
Prepaid expenses	1,174	1,139
Other current assets	9	1,485
Total current assets	16,022	25,219
Property and equipment, net	460	541
Operating lease right-of-use asset	563	656
Restricted cash	360	360
Total assets	17,405	26,776
Current liabilities:
Accounts payable	909	1,280
Accrued liabilities	1,322	2,930
Current portion of long-term debt	606	1,333
Current portion of operating lease liabilities	370	360
Deferred revenue	5,000	5,000
Total current liabilities	8,207	10,903
Long-term debt	385	3,819
Operating lease liabilities	689	897
Total liabilities	9,281	15,619
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at September 30, 2020 and December 31, 2019
Common stock, $0.001 par value; 100,000,000 shares authorized at September 30, 2020 and December 31, 2019; 48,227,442 and 44,413,372 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	48	44
Additional paid-in capital	256,831	248,770
Accumulated deficit	(248,755)	(237,657)
Total stockholders’ equity	8,124	11,157
Total liabilities and stockholders’ equity	$ 17,405	$ 26,776

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	48,227,442	44,413,372
Common stock, shares outstanding	48,227,442	44,413,372

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
License and other revenue	$ 3,432	$ 141	$ 7,883	$ 231
Type of Revenue [Extensible List]			clsd:LicenseAndOtherRevenueMember	clsd:LicenseAndOtherRevenueMember
Operating expenses:
Research and development	3,490	2,728	$ 10,601	$ 14,353
General and administrative	2,374	3,781	8,107	13,169
Total operating expenses	5,864	6,509	18,708	27,522
Loss from operations	(2,432)	(6,368)	(10,825)	(27,291)
Other expense	(1)	(168)	(273)	(383)
Net loss	$ (2,433)	$ (6,536)	$ (11,098)	$ (27,674)
Net loss per share of common stock — basic and diluted	$ (0.05)	$ (0.17)	$ (0.24)	$ (0.75)
Weighted average shares outstanding — basic and diluted	46,976,649	38,414,751	45,653,068	36,747,314

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In-Capital	Accumulated Deficit
Beginning balance at Dec. 31, 2018	$ 23,620	$ 32	$ 230,475	$ (206,887)
Beginning balance, shares at Dec. 31, 2018		32,119,227
Issuance of common shares under at-the-market sales agreement	6,627	$ 5	6,622
Issuance of common shares under at-the-market sales agreement, shares		4,660,966
Exercise of stock options	1		1
Exercise of stock options, shares		2,727
Share-based compensation expense	1,247		1,247
Net loss	(15,404)			(15,404)
Ending balance at Mar. 31, 2019	16,091	$ 37	238,345	(222,291)
Ending balance, shares at Mar. 31, 2019		36,782,920
Beginning balance at Dec. 31, 2018	23,620	$ 32	230,475	(206,887)
Beginning balance, shares at Dec. 31, 2018		32,119,227
Net loss	(27,674)
Ending balance at Sep. 30, 2019	9,759	$ 41	244,279	(234,561)
Ending balance, shares at Sep. 30, 2019		41,149,781
Beginning balance at Mar. 31, 2019	16,091	$ 37	238,345	(222,291)
Beginning balance, shares at Mar. 31, 2019		36,782,920
Issuance of common shares under at-the-market sales agreement	1,273	$ 1	1,272
Issuance of common shares under at-the-market sales agreement, shares		945,974
Issuance of common shares under employee stock purchase plan	15		15
Issuance of common shares under employee stock purchase plan, shares		17,252
Share-based compensation expense	1,256		1,256
Net loss	(5,734)			(5,734)
Ending balance at Jun. 30, 2019	12,901	$ 38	240,888	(228,025)
Ending balance, shares at Jun. 30, 2019		37,746,146
Issuance of common shares under at-the-market sales agreement	2,419	$ 3	2,416
Issuance of common shares under at-the-market sales agreement, shares		3,370,000
Vesting of restricted stock units, shares		20,000
Exercise of stock options	5		5
Exercise of stock options, shares		13,635
Share-based compensation expense	970		970
Net loss	(6,536)			(6,536)
Ending balance at Sep. 30, 2019	9,759	$ 41	244,279	(234,561)
Ending balance, shares at Sep. 30, 2019		41,149,781
Beginning balance at Dec. 31, 2019	11,157	$ 44	248,770	(237,657)
Beginning balance, shares at Dec. 31, 2019		44,413,372
Issuance of common shares under at-the-market sales agreement	1,193	$ 1	1,192
Issuance of common shares under at-the-market sales agreement, shares		455,186
Share-based compensation expense	1,001		1,001
Net loss	(2,911)			(2,911)
Ending balance at Mar. 31, 2020	10,440	$ 45	250,963	(240,568)
Ending balance, shares at Mar. 31, 2020		44,868,558
Beginning balance at Dec. 31, 2019	11,157	$ 44	248,770	(237,657)
Beginning balance, shares at Dec. 31, 2019		44,413,372
Net loss	(11,098)
Ending balance at Sep. 30, 2020	8,124	$ 48	256,831	(248,755)
Ending balance, shares at Sep. 30, 2020		48,227,442
Beginning balance at Mar. 31, 2020	10,440	$ 45	250,963	(240,568)
Beginning balance, shares at Mar. 31, 2020		44,868,558
Issuance of common shares under at-the-market sales agreement	1,607	$ 1	1,606
Issuance of common shares under at-the-market sales agreement, shares		800,170
Vesting of restricted stock units, shares		512,550
Exercise of stock options	72		72
Exercise of stock options, shares		58,333
Issuance of common shares under employee stock purchase plan	31		31
Issuance of common shares under employee stock purchase plan, shares		35,359
Share-based compensation expense	891		891
Net loss	(5,754)			(5,754)
Ending balance at Jun. 30, 2020	7,287	$ 46	253,563	(246,322)
Ending balance, shares at Jun. 30, 2020		46,274,970
Issuance of common shares under at-the-market sales agreement	2,285	$ 2	2,283
Issuance of common shares under at-the-market sales agreement, shares		1,382,564
Vesting of restricted stock units, shares		375,025
Exercise of stock options	144		144
Exercise of stock options, shares		194,883
Share-based compensation expense	841		841
Net loss	(2,433)			(2,433)
Ending balance at Sep. 30, 2020	$ 8,124	$ 48	$ 256,831	$ (248,755)
Ending balance, shares at Sep. 30, 2020		48,227,442

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net loss	$ (11,098)	$ (27,674)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	136	160
Share-based compensation expense	2,733	3,473
Non-cash interest expense	59	141
Accretion of debt discount	129	46
Amortization and accretion on available-for-sale investments, net		(115)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,441	571
Other assets and liabilities	(105)	306
Accounts payable and accrued liabilities	(1,979)	(5,665)
Net cash used in operating activities	(8,684)	(28,757)
Investing activities
Maturities of available-for-sale investments		32,950
Acquisition of property and equipment	(55)	(25)
Net cash (used in) provided by investing activities	(55)	32,925
Financing activities
Proceeds from long-term debt	991
Payments made on long-term debt	(5,340)
Proceeds from at-the-market sales agreement, net of issuance costs	5,084	10,319
Proceeds from exercise of stock options	217	6
Proceeds from shares issued under employee stock purchase plan	31	15
Net cash provided by financing activities	983	10,340
Net (decrease) increase in cash, cash equivalents and restricted cash	(7,756)	14,508
Cash, cash equivalents and restricted cash, beginning of period	22,955	8,403
Cash, cash equivalents and restricted cash, end of period	15,199	22,911
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	14,839	22,551
Restricted cash	360	360
Cash, cash equivalents and restricted cash, end of period	$ 15,199	$ 22,911

The Company

The Company	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company	1. The Company Clearside Biomedical, Inc. (the “Company”) is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. The Company’s proprietary SCS Microinjector targets the suprachoroidal space and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. This suprachoroidal space injection is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations, such as gene therapy . Incorporated in the State of Delaware on May 26, 2011, the Company has its corporate headquarters in Alpharetta, Georgia. The Company’s activities primarily consist of developing product and technology rights and performing research and development activities. The Company has no current source of revenue to sustain present activities, and does not expect to generate meaningful revenue until and unless the Company receives regulatory approval of and successfully commercializes its product candidates, either on its own or with a third party. The Company is subject to a number of risks and uncertainties similar to those of other life science companies at a similar stage of development, including, among others, the need to obtain adequate additional financing, successful development efforts including regulatory approval of products, compliance with government regulations, successful commercialization of potential products, protection of proprietary technology and dependence on key individuals. Liquidity The Company had cash and cash equivalents of $14.8 million as of September 30, 2020. The Company has funded its operations primarily through the sale of convertible preferred stock and common stock and the issuance of long-term debt. The Company has suffered recurring losses and negative cash flows from operations since inception and anticipates incurring additional losses until such time, if ever, that it can obtain regulatory approval to sell, and then generate significant revenue from commercializing its lead product candidate, XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) with its licensees. In the absence of product or other revenues, the amount, timing, nature or source of which cannot be predicted, the Company’s losses will continue as it conducts its research and development activities. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. Until the Company can generate sufficient revenue, the Company will need to finance future cash needs through public or private equity offerings, license agreements, debt financings or restructurings, collaborations, strategic alliances and marketing or distribution arrangements. The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result should the Company be unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Basis of Presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Unaudited Interim Financial Information The accompanying balance sheet as of September 30, 2020, statements of operations for the three and nine months ended September 30, 2020 and 2019, statements of stockholders’ equity for the three and nine months ended September 30, 2020 and 2019 and statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2020, its results of its operations for the three and nine months ended September 30, 2020 and 2019, its changes in stockholders’ equity for the three and nine months ended September 30, 2020 and 2019 and its cash flows for the nine months ended September 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2020 and 2019 are unaudited. The results for the nine months ended September 30, 2020 are not indicative of results to be expected for the year ending December 31, 2020, any other interim periods or any future year or period. These unaudited financial statements should be read in conjunction with the audited financial statements and related footnotes, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include the accounting for useful lives to calculate depreciation and amortization, clinical expense accruals, share-based compensation expense and income tax valuation allowance. Actual results could differ from these estimates. Effects of COVID-19 The COVID-19 pandemic is expected to continue to result in a global slowdown of economic activity. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our financial statements. Revenue Recognition The Company recognizes revenue from its contracts with customers under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers The Company receives payments from its customers based on billing schedules established in each contract. Upfront and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangement. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. Research and Development Costs Research and development costs are charged to expense as incurred and include: • employee-related expenses, including salaries, benefits, travel and share-based compensation expense for research and development personnel; • expenses incurred under agreements with contract research organizations, contract manufacturing organizations and consultants that conduct clinical trials and preclinical studies; • costs associated with preclinical and clinical development activities; • costs associated with submitting regulatory approval applications for the Company’s product candidates; • costs associated with training physicians on the suprachoroidal injection procedure and educating and providing them with appropriate product candidate information; • costs associated with technology and intellectual property licenses; • costs for the Company’s research and development facility; and • depreciation expense for assets used in research and development activities. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the financial statements as prepaid or accrued expense. Share-Based Compensation Compensation cost related to share-based awards granted to employees is measured based on the estimated fair value of the award at the grant date. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The fair value of restricted stock units granted is measured based on the market value of the Company’s common stock on the date of grant. Share-based compensation costs are expensed on a straight-line basis over the relevant vesting period. Compensation cost related to shares purchased through the Company’s employee stock purchase plan, which is considered compensatory, is based on the estimated fair value of the shares on the offering date, including consideration of the discount and the look back period. The Company estimates the fair value of the shares using a Black-Scholes option pricing model. Compensation expense is recognized over the six-month withholding period prior to the purchase date. All share-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying employees’ roles within the Company. Cash Equivalents Cash equivalents consist of short-term, highly liquid investments with an original term of three months or less at the date of purchase. Concentration of Credit Risk Arising From Cash Deposits in Excess of Insured Limits The Company maintains its cash in bank deposits that at times may exceed federally insured limits. The Company has not experienced any loss in such accounts. The Company believes it is not exposed to any significant risks with respect to its cash balances. Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement Fair Value Measurements and Disclosures In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. The Company adopted ASU 2016-13 on January 1, 2020, and the adoption did not have a material impact on its financial statements and related disclosures. Recent Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Property and Equipment, Net	3. Property and Equipment, Net Property and equipment, net consisted of the following (dollar amounts in thousands): Estimated Useful Lives (Years) September 30, 2020 December 2019 Furniture and fixtures 5 $ 337 $ 337 Machinery and equipment 5 176 121 Computer equipment 3 13 13 Leasehold improvements Lesser of useful life remaining lease term 667 667 1,193 1,138 Less: Accumulated depreciation (733 ) (597 ) $ 460 $ 541

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2020
Payables And Accruals [Abstract]
Accrued Liabilities	4. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): September 30, December 2020 2019 Accrued research and development $ 110 $ 359 Accrued employee costs 950 1,530 Accrued severance 86 751 Accrued professional fees 32 58 Accrued expense 144 232 $ 1,322 $ 2,930

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Long-Term Debt	5. Long-Term Debt Loan and Security Agreements On May 14, 2018, the Company entered into a second amended and restated loan and security agreement (the “2 nd nd nd The Company borrowed an initial tranche of $10.0 million on May 14, 2018, of which $7.0 million was used to repay all amounts outstanding under the first amended and restated loan agreement, including fees associated with the final payment. The prepayment fees were waived. Of the remaining $10.0 million under the 2 nd On October 18, 2019, the Company entered into an amendment to the 2 nd nd On May 7, 2020, due to various restrictions and other limiting covenants of the 2 nd the Company $5.0 million principal balance, plus $0.3 million reflecting the final payment fee and accrued interest. The prepayment fees were waived by the lender. As a result of the prepayment, there was no interest expense, accretion of the final payment or accretion of the deferred debt issuance costs on the borrowings under the 2 nd

CARES Act Paycheck Protection P

CARES Act Paycheck Protection Program Loan	9 Months Ended
	Sep. 30, 2020
Extraordinary And Unusual Items [Abstract]
CARES Act Paycheck Protection Program Loan	6 . CARES Act Paycheck Protection Program Loan On April 20, 2020, the Company entered into a loan agreement with Silicon Valley Bank (the “PPP Lender”) under the terms of which the PPP Lender made a loan to the Company in an aggregate principal amount of $1.0 million (the “PPP Loan”) pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The PPP Loan is evidenced by a promissory note (the “Note”) containing the terms and conditions for repayment of the PPP Loan. Under the terms of the Note and the PPP Loan, interest a The CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. Under the PPP, the Company may apply for forgiveness for all or a portion of the PPP Loan based on a formula that takes into account a number of factors, including the amount of loan proceeds used by the Company during the 24- 60 The Note may be prepaid in part or in full, at any time, without penalty. The Note provides for certain customary events of default, including (i) failing to make a payment when due under the Note, (ii) failure to do anything required by the Note or any other loan document, (iii) defaults of any other loan with the PPP Lender, (iv) failure to disclose any material fact or making a materially false or misleading representation to the PPP Lender or U.S. Small Business Administration (“SBA”), (v) default on any loan or agreement with another creditor, if the PPP Lender believes the default may materially affect the Company’s ability to pay the Note, (vi) failure to pay any taxes when due, (vii) becoming the subject of a proceeding under any bankruptcy or insolvency law, having a receiver or liquidator appointed for any part of the Company’s business or property, or making an assignment for the benefit of creditors, (viii) having any adverse change in financial condition or business operation that the PPP Lender believes may materially affect the Company’s ability to pay the Note, (ix) if the Company reorganizes, merges, consolidates, or otherwise changes ownership or business structure without the PPP Lender’s prior written consent, or (x) becoming the subject of a civil or criminal action that the PPP Lender believes may materially affect the Company’s ability to pay the Note. Upon the occurrence of an event of default, the PPP Lender has customary remedies and may, among other things, require immediate payment of all amounts owed under the Note, collect all amounts owing from the Company, and file suit and obtain judgment against the Company. As of September 30, 2020, in connection with the PPP Loan, the Company recorded $0.6 million in short-term debt and $0.4 million in long-term debt.

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Common Stock	7. Common Stock The Company’s amended and restated certificate of incorporation authorizes the Company to issue 100,000,000 shares of $0.001 par value common stock. As of September 30, 2020 and December 31, 2019, there were 48,227,442 and 44,413,372 shares of common stock outstanding, respectively.

Stock Purchase Warrants

Stock Purchase Warrants	9 Months Ended
	Sep. 30, 2020
Stock Purchase Warrants [Abstract]
Stock Purchase Warrants	8. Stock Purchase Warrants In September 2016, in connection with a loan agreement, the Company issued warrants to purchase up to 29,796 shares of common stock at a price per share of $10.74. The warrants expire in September 2026, or earlier upon the occurrence of specified mergers or acquisitions of the Company, and are immediately exercisable .

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	9. Share-Based Compensation Share-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation Stock Options The Company has granted stock option awards to employees, directors and consultants from its 2011 Stock Incentive Plan (the “2011 Plan”) and its 2016 Equity Incentive Plan (the “2016 Plan”). The estimated fair value of options granted is determined as of the date of grant using the Black-Scholes option pricing model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the awards. Share-based compensation expense for options granted under the 2011 Plan and the 2016 Plan is reflected in the statements of operations as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Research and development $ 290 $ 243 $ 881 $ 1,066 General and administrative 384 543 1,176 2,166 Total $ 674 $ 786 $ 2,057 $ 3,232 The following table summarizes the activity related to stock options during the nine months ended September 30, 2020: Weighted Number of Average Shares Exercise Price Options outstanding at December 31, 2019 4,104,450 $ 4.63 Granted 1,100,250 2.31 Exercised (253,216 ) 0.89 Forfeited (702,041 ) 6.49 Options outstanding at September 30, 2020 4,249,443 3.95 Options exercisable at December 31, 2019 2,452,764 5.44 Options exercisable at September 30, 2020 2,225,536 4.97 As of September 30, 2020, the Company had $4.1 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 2.3 years. Restricted Stock Units The Company has granted restricted stock units (“RSUs”) to employees from the 2016 Plan. The shares underlying the RSU awards have vesting terms of one to four years from the date of grant subject to the employees’ continuous service and subject to accelerated vesting in specified circumstances. The fair value of the RSUs granted is measured based on the market value of the Company’s common stock on the date of grant and is recognized ratably over the requisite service period, which is generally the vesting period of the awards. The following table summarizes the activity related to RSUs during the nine months ended September 30, 2020: Weighted Average Number of Grant Date Shares Fair Value Non-vested RSUs outstanding at December 31, 2019 1,269,300 $ 0.87 Granted 486,000 2.39 Vested (887,575 ) 0.93 Forfeited (6,700 ) 0.91 Non-vested RSUs outstanding at September 30, 2020 861,025 1.67 The Company recorded $0.2 million and $45,000 of share-based compensation expense for the three months ended September 30, 2020 and 2019, respectively, and $0.7 million and $0.2 million for the nine months ended September 30, 2020 and 2019, respectively, for the RSUs. As of September 30, 2020, the Company had $1.2 million of unrecognized compensation expense related to the RSUs, which is expected to be recognized over a weighted average period of 2.6 years. Employee Stock Purchase Plan The 2016 Employee Stock Purchase Plan (the “2016 ESPP”) became effective on June 1, 2016. The 2016 ESPP is considered a compensatory plan and the fair value of the discount and the look-back period are estimated using the Black-Scholes option pricing model and expense is recognized over the six-month withholding period prior to the purchase date. The Company recorded $17,000 and $2,000 of share-based compensation expense for the three months ended September 30, 2020 and 2019, respectively, and $24,000 and $15,000 for the nine months ended September 30, 2020 and 2019, respectively, in the statements of operations for the estimated number of shares to be purchased on the next purchase date following the conclusion of the applicable reporting period. During the nine months ended September 30, 2020, the Company issued 35,359 shares of common stock purchased under the 2016 ESPP.

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Lease Commitment Summary In November 2016, the Company signed an office lease agreement to lease approximately 20,000 square feet of office space in Alpharetta, Georgia for its corporate headquarters. The lease agreement is for a 6.5 year term with a renewal option for one additional five-year term. Rental payments are $35,145 per month subject to an increase of 3% per year. Rent expense under this lease is recognized on a straight-line basis over the term of the lease. In addition, the lease agreement requires payment of the pro-rata share of the annual operating expenses associated with the premises. The Company’s operating leases included on the balance sheet are as follows (in thousands): September 30, 2020 Operating lease right-of-use asset $ 563 Liabilities Current portion of operating lease liabilities $ 370 Operating lease liabilities 689 Total operating lease liabilities $ 1,059 The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company’s obligation to make payments over the lease term. The renewal option is not included in the calculation of the right-of-use asset and the lease liabilities as the Company has not yet determined if the Alpharetta, Georgia lease will be renewed. The present value of the lease payments is calculated using an incremental borrowing rate as the Company’s leases do not provide an implicit interest rate. At September 30, 2020, the Company’s weighted average discount rate was 11.0% and the weighted average lease term was 3.0 years. Minimum lease payments were as follows at September 30, 2020 (in thousands): Year Ending December 31, 2020 95 2021 392 2022 407 2023 316 Total minimum lease payments 1,210 Less imputed interest (151 ) Total operating lease liabilities $ 1,059 Equipment leases with an initial term of 12 months or less are not recorded with operating lease liabilities. The Company recognizes expense for these leases on a straight-line basis over the lease term. The equipment leases were deemed to be immaterial. Operating lease cost was $62,000 and $100,000 for the three months ended September 30, 2020 and 2019, respectively, and $185,000 and $300,000 for the nine months ended September 30, 2020 and 2019, respectively. Variable lease cost was $24,000 and $36,000 for the three months ended September 30, 2020 and 2019, respectively, and $71,000 and $122,000 for the nine months ended September 30, 2020 and 2019, respectively. Short-term lease cost was $2,000 and $4,000 for the three months ended September 30, 2020 and 2019, respectively, and $10,000 and $13,000 for the nine months ended September 30, 2020 and 2019, respectively. Cash payments included in operating activities on the statement of cash flows for operating lease liabilities were $283,000 and $389,000 for the nine months ended September 30, 2020 and 2019, respectively. Contract Service Providers In the course of the Company’s normal business operations, it has agreements with contract service providers to assist in the performance of its research and development, clinical research and manufacturing. Substantially all of these contracts are on an as needed basis.

License and Other Agreements

License and Other Agreements	9 Months Ended
	Sep. 30, 2020
License And Other Agreement [Abstract]
License and Other Agreements	11. License and Other Agreements Bausch License Agreement Amendment On April 27, 2020, the Company and Bausch Health Ireland Limited (“Bausch”) entered into an amendment (the “Amendment”) to the Company’s License Agreement with Bausch dated October 22, 2019 (as amended, the “Bausch License Agreement”). Pursuant to the Bausch License Agreement, the Company has granted an exclusive license to Bausch to develop, manufacture, distribute, promote, market and commercialize XIPERE, the Company’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye using the Company’s proprietary microinjector (the “Device”), as well as specified other steroids, corticosteroids and NSAIDs in combination with the Device (“Other Products”; and together with XIPERE, “Products”), subject to specified exceptions, in the United States and Canada (the “Original Territory”) for the treatment of ophthalmology indications, including non-infectious uveitis. Pursuant to the Amendment, the Company has granted Bausch an exclusive option (the “Option”) to develop, manufacture, distribute, promote, market and commercialize XIPERE in one or more of the following regions: (i) the European Union, including the United Kingdom, (ii) Australia and New Zealand and (iii) South America and Mexico (such regions, the “Additional Regions” and together with the Original Territory, the “Territory”). The Option may be exercised any time before the earlier of regulatory approval of XIPERE in the United States and August 31, 2021. Pursuant to the Bausch License Agreement, Bausch paid the Company an upfront payment of $5.0 million (the “Upfront Payment”) in October 2019, which is subject to a refund if the Bausch License Agreement is terminated in specified circumstances. In addition, Bausch has agreed to make additional payments of up to $15.0 million upon the achievement of specified pre-launch development and regulatory milestones (the “Pre-Launch Milestone Payments”) and up to an aggregate of $57.3 million in additional milestone payments upon the achievement of (i) specified regulatory approvals for specified additional indications of XIPERE (including certain regulatory and commercial milestones if Bausch exercises its Option in the European Union) and (ii) specified levels of annual net sales (as defined in the Bausch License Agreement). Further, during the applicable royalty term, the Company will also be entitled to receive tiered royalties at increasing percentages, from the high-teens to twenty percent, based on XIPERE achieving certain annual net sales thresholds in the Original Territory, as well as a lower royalty on annual net sales of Other Products in the Original Territory and on annual net sales of Xipere During the term of the Bausch License Agreement, and in the Territory, the Company has agreed not to (i) develop or commercialize XIPERE alone or in combination with an Other Device (as defined in the Bausch License Agreement) in the licensed field, (ii) develop or commercialize any corticosteroid with the Device or an Other Device in the licensed field, (iii) develop or commercialize the Device or an Other Device with any active pharmaceutical ingredient for non-infectious uveitis or macular edema associated with non-infectious uveitis, including with any Other Drug (as defined in the Bausch License Agreement, which are restricted to those steroids, corticosteroids and non-steroidal anti-inflammatory drugs specifically identified in the Bausch License Agreement), (iv) develop or commercialize any Other Drug in combination with the Device and (v) commercialize any Other Device for achieving non-surgical access to the suprachoroidal space where such device is sold as a stand-alone product, subject to specified exceptions. The Bausch License Agreement will expire upon expiration of the royalty terms for all Products and countries in the Territory, with each royalty term for a given Product and country ending on the latest of (i) the date of expiration of the last-to-expire valid claim of any licensed patent rights covering such Product in such country in the Territory, (ii) the date of the loss of regulatory exclusivity for such Product in such country in the Territory, or (iii) ten years from the later of the first sale of such Product in such country in the Territory. For a specified period of time, Bausch may terminate the Bausch License Agreement immediately and have the Upfront Payment refunded if the U.S. Food and Drug Administration (the “FDA”) has not approved the Company’s New Drug Application (“NDA”) for XIPERE by August 31, 2021. Following the payment of the Pre-Launch Milestone Payments, Bausch may also terminate the Bausch License Agreement for convenience upon 180 days’ written notice. In addition, the Company can terminate the Bausch License Agreement if Bausch commences a legal action challenging the validity, enforceability or scope of any of the licensed patents. If the FDA requires an additional clinical trial prior to approving the NDA for XIPERE and the Company notifies Bausch that the Company will not conduct the trial at the Company’s expense, then Bausch may terminate the Bausch License Agreement and have the Upfront Payment refunded within 60 days of the receipt of such notice from the Company. Both parties may terminate the Bausch License Agreement (i) upon a material breach of the Bausch License Agreement, subject to a specified cure period and specified exceptions, or (ii) if the other party encounters bankruptcy or insolvency. Upon termination (other than for a material breach by or bankruptcy or insolvency event of the Company), all licenses and other rights granted by the Company to Bausch pursuant to the Bausch License Agreement would revert to the Company. The Company is responsible for all development expenses for XIPERE in the Original Territory until the NDA NDA Arctic Vision (Hong Kong) Limited On March 10, 2020, the Company entered into a License Agreement (the “Arctic License Agreement”) with Arctic Vision (Hong Kong) Limited (“Arctic Vision”). Pursuant to the Arctic License Agreement, the Company has granted an exclusive license to Arctic Vision to develop, distribute, promote, market and commercialize XIPERE, the Company’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye using the Company’s proprietary SCS Microinjector, subject to specified exceptions, in China, Hong Kong, Macau, Taiwan and South Korea (the “Arctic Territory”). Under the terms of the Arctic License Agreement, neither party may commercialize XIPERE in the other party’s territory. Arctic Vision has agreed to use commercially reasonably efforts to pursue development and commercialization of XIPERE for indications associated with uveitis in the Arctic Territory. In addition, upon receipt of the Company’s consent, Arctic Vision will have the right, but not the obligation, to develop and commercialize XIPERE for additional indications in the Arctic Territory. Pursuant to the Arctic License Agreement, Arctic Vision has agreed to pay the Company up to a total of $35.5 million. This amount includes an upfront payment of $4.0 million as well as an aggregate of up to $31.5 million in development milestone payments for specified events prior to and including receipt of approval of XIPERE in the United States and sales milestone payments for achievement of specified levels of net sales. Further, during the applicable royalty term, the Company will also be entitled to receive tiered royalties of ten to twelve percent of net sales based on achieving certain annual net sales thresholds in the Arctic Territory, subject to customary reductions, payable on a product-by-product and country-by-country basis, commencing at launch in such country and lasting until the latest of (i) the date that all valid claims within the licensed patent rights covering XIPERE have expired, (ii) the date of the loss of marketing or regulatory exclusivity of XIPERE in a given country, or (iii) ten years from the first commercial sale of XIPERE in a given country. As of March 31, 2020, the Company had completed its performance obligations related to the upfront payment and recognized license revenue of $4.0 million during the three months ended March 31, 2020. Other The Company has periodically entered into other short-term agreements, generally with performance obligations of one to two months, to evaluate the potential use of its proprietary SCS Microinjector with third-party product candidates for the treatment of various diseases. Funds received from these agreements are recognized as revenue over the term of the agreement. The Company did not record any revenue from these agreements for the three months ended September 30, 2020. The Company recorded $15,000 of revenue from these agreements during the three months ended September 30, 2019, and $0.2 million and $0.1 million for the nine months ended September 30, 2020 and 2019, respectively.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	12. Fair Value Measurements The Company records certain financial assets and liabilities at fair value in accordance with the provisions of ASC Topic 820, Fair Value Measurements and Disclosures • Level 1—Unadjusted quoted prices in active, accessible markets for identical assets or liabilities. • Level 2—Other inputs that are directly or indirectly observable in the marketplace. • Level 3—Unobservable inputs that are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s material financial instruments at September 30, 2020 and December 31, 2019 consisted primarily of cash and cash equivalents and long-term debt. The fair values of cash and cash equivalents, other current assets and accounts payable approximate their respective carrying values due to the short term nature of these instruments and are classified as Level 1 in the fair value hierarchy. The fair value of long-term debt approximates the carrying value due to variable interest rates that correspond to market rates and is classified as Level 1 in the fair value hierarchy. There were no significant transfers between Levels 1, 2 and 3 during the nine months ended September 30, 2020 and the year ended December 31, 2019. The following tables summarize the fair value of financial assets that are measured at fair value and the classification by level of input within the fair value hierarchy (in thousands): September 30, 2020 Level 1 Level 2 Level 3 Recorded Value Financial Assets: Cash and money markets $ 14,839 $ — $ — $ 14,839 Restricted cash money market 360 — — 360 Total financial assets $ 15,199 $ — $ — $ 15,199 December 31, 2019 Level 1 Level 2 Level 3 Recorded Value Financial Assets: Cash and money markets $ 22,595 $ — $ — $ 22,595 Restricted cash money market 360 — — 360 Total financial assets $ 22,955 $ — $ — $ 22,955

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration of the dilutive effect of potential common stock equivalents. Diluted net loss per share gives effect to all dilutive potential shares of common stock outstanding during this period. For all periods presented, the Company’s potential common stock equivalents, which included stock options, restricted stock units and stock purchase warrants, have been excluded from the computation of diluted net loss per share as their inclusion would have the effect of reducing the net loss per share. Therefore, the denominator used to calculate both basic and diluted net loss per share is the same in all periods presented. The Company’s potential common stock equivalents that have been excluded from the computation of diluted net loss per share for all periods presented because of their antidilutive effect consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Outstanding stock options 4,249,443 4,192,884 4,249,443 4,192,884 Non-vested restricted stock units 861,025 1,319,300 861,025 1,319,300 Stock purchase warrants 29,796 29,796 29,796 29,796 5,140,264 5,541,980 5,140,264 5,541,980

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying balance sheet as of September 30, 2020, statements of operations for the three and nine months ended September 30, 2020 and 2019, statements of stockholders’ equity for the three and nine months ended September 30, 2020 and 2019 and statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2020, its results of its operations for the three and nine months ended September 30, 2020 and 2019, its changes in stockholders’ equity for the three and nine months ended September 30, 2020 and 2019 and its cash flows for the nine months ended September 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2020 and 2019 are unaudited. The results for the nine months ended September 30, 2020 are not indicative of results to be expected for the year ending December 31, 2020, any other interim periods or any future year or period. These unaudited financial statements should be read in conjunction with the audited financial statements and related footnotes, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include the accounting for useful lives to calculate depreciation and amortization, clinical expense accruals, share-based compensation expense and income tax valuation allowance. Actual results could differ from these estimates.
Effects of COVID-19	Effects of COVID-19 The COVID-19 pandemic is expected to continue to result in a global slowdown of economic activity. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our financial statements.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from its contracts with customers under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers The Company receives payments from its customers based on billing schedules established in each contract. Upfront and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangement. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and include: • employee-related expenses, including salaries, benefits, travel and share-based compensation expense for research and development personnel; • expenses incurred under agreements with contract research organizations, contract manufacturing organizations and consultants that conduct clinical trials and preclinical studies; • costs associated with preclinical and clinical development activities; • costs associated with submitting regulatory approval applications for the Company’s product candidates; • costs associated with training physicians on the suprachoroidal injection procedure and educating and providing them with appropriate product candidate information; • costs associated with technology and intellectual property licenses; • costs for the Company’s research and development facility; and • depreciation expense for assets used in research and development activities. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the financial statements as prepaid or accrued expense.
Share-Based Compensation	Share-Based Compensation Compensation cost related to share-based awards granted to employees is measured based on the estimated fair value of the award at the grant date. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The fair value of restricted stock units granted is measured based on the market value of the Company’s common stock on the date of grant. Share-based compensation costs are expensed on a straight-line basis over the relevant vesting period. Compensation cost related to shares purchased through the Company’s employee stock purchase plan, which is considered compensatory, is based on the estimated fair value of the shares on the offering date, including consideration of the discount and the look back period. The Company estimates the fair value of the shares using a Black-Scholes option pricing model. Compensation expense is recognized over the six-month withholding period prior to the purchase date. All share-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying employees’ roles within the Company.
Cash Equivalents	Cash Equivalents Cash equivalents consist of short-term, highly liquid investments with an original term of three months or less at the date of purchase.
Concentration of Credit Risk Arising From Cash Deposits in Excess of Insured Limits	Concentration of Credit Risk Arising From Cash Deposits in Excess of Insured Limits The Company maintains its cash in bank deposits that at times may exceed federally insured limits. The Company has not experienced any loss in such accounts. The Company believes it is not exposed to any significant risks with respect to its cash balances.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement Fair Value Measurements and Disclosures In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. The Company adopted ASU 2016-13 on January 1, 2020, and the adoption did not have a material impact on its financial statements and related disclosures. Recent Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following (dollar amounts in thousands): Estimated Useful Lives (Years) September 30, 2020 December 2019 Furniture and fixtures 5 $ 337 $ 337 Machinery and equipment 5 176 121 Computer equipment 3 13 13 Leasehold improvements Lesser of useful life remaining lease term 667 667 1,193 1,138 Less: Accumulated depreciation (733 ) (597 ) $ 460 $ 541

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Payables And Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): September 30, December 2020 2019 Accrued research and development $ 110 $ 359 Accrued employee costs 950 1,530 Accrued severance 86 751 Accrued professional fees 32 58 Accrued expense 144 232 $ 1,322 $ 2,930

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Summary of Share-based Compensation Expense	Share-based compensation expense for options granted under the 2011 Plan and the 2016 Plan is reflected in the statements of operations as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Research and development $ 290 $ 243 $ 881 $ 1,066 General and administrative 384 543 1,176 2,166 Total $ 674 $ 786 $ 2,057 $ 3,232
Stock Options
Summary of Activity Related to Stock Options	The following table summarizes the activity related to stock options during the nine months ended September 30, 2020: Weighted Number of Average Shares Exercise Price Options outstanding at December 31, 2019 4,104,450 $ 4.63 Granted 1,100,250 2.31 Exercised (253,216 ) 0.89 Forfeited (702,041 ) 6.49 Options outstanding at September 30, 2020 4,249,443 3.95 Options exercisable at December 31, 2019 2,452,764 5.44 Options exercisable at September 30, 2020 2,225,536 4.97
Restricted Stock Units (RSUs)
Summary of the Activity Related to RSUs	The following table summarizes the activity related to RSUs during the nine months ended September 30, 2020: Weighted Average Number of Grant Date Shares Fair Value Non-vested RSUs outstanding at December 31, 2019 1,269,300 $ 0.87 Granted 486,000 2.39 Vested (887,575 ) 0.93 Forfeited (6,700 ) 0.91 Non-vested RSUs outstanding at September 30, 2020 861,025 1.67

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Operating Leases Included on the Balance Sheet	The Company’s operating leases included on the balance sheet are as follows (in thousands): September 30, 2020 Operating lease right-of-use asset $ 563 Liabilities Current portion of operating lease liabilities $ 370 Operating lease liabilities 689 Total operating lease liabilities $ 1,059
Future Minimum Commitments Due Under Non-Cancelable Operating Leases	Minimum lease payments were as follows at September 30, 2020 (in thousands): Year Ending December 31, 2020 95 2021 392 2022 407 2023 316 Total minimum lease payments 1,210 Less imputed interest (151 ) Total operating lease liabilities $ 1,059

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Summary of Assets Measured at Fair Value	The following tables summarize the fair value of financial assets that are measured at fair value and the classification by level of input within the fair value hierarchy (in thousands): September 30, 2020 Level 1 Level 2 Level 3 Recorded Value Financial Assets: Cash and money markets $ 14,839 $ — $ — $ 14,839 Restricted cash money market 360 — — 360 Total financial assets $ 15,199 $ — $ — $ 15,199 December 31, 2019 Level 1 Level 2 Level 3 Recorded Value Financial Assets: Cash and money markets $ 22,595 $ — $ — $ 22,595 Restricted cash money market 360 — — 360 Total financial assets $ 22,955 $ — $ — $ 22,955

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Potential Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share	The Company’s potential common stock equivalents that have been excluded from the computation of diluted net loss per share for all periods presented because of their antidilutive effect consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Outstanding stock options 4,249,443 4,192,884 4,249,443 4,192,884 Non-vested restricted stock units 861,025 1,319,300 861,025 1,319,300 Stock purchase warrants 29,796 29,796 29,796 29,796 5,140,264 5,541,980 5,140,264 5,541,980

The Company - Additional Inform

The Company - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Entity incorporation date	May 26, 2011
Cash and cash equivalents	$ 14,839	$ 22,595	$ 22,551

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and Equipment, gross	$ 1,193	$ 1,138
Less: Accumulated depreciation	(733)	(597)
Property and equipment, net	460	541
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and Equipment, gross	$ 337	337
Estimated Useful Lives (Years)	5 years
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and Equipment, gross	$ 176	121
Estimated Useful Lives (Years)	5 years
Computer Equipment
Property Plant And Equipment [Line Items]
Property and Equipment, gross	$ 13	13
Estimated Useful Lives (Years)	3 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and Equipment, gross	$ 667	$ 667
Estimated Useful Lives (Years)	Lesser of useful life or remaining lease term

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued research and development	$ 110	$ 359
Accrued employee costs	950	1,530
Accrued severance	86	751
Accrued professional fees	32	58
Accrued expense	144	232
Accrued liabilities, current	$ 1,322	$ 2,930

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) - USD ($)	May 07, 2020	Oct. 18, 2019	May 14, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Interest expense on borrowings				$ 0	$ 223,000	$ 147,000	$ 676,000
Accretion of scheduled final payment				0	47,000	59,000	141,000
Accretion of deferred debt issuance costs				$ 0	$ 16,000	$ 129,000	$ 47,000
Second Amended and Restated Loan and Security Agreement
Debt Instrument [Line Items]
Long term debt		$ 10,000,000
Repayment of outstanding amount under the loan agreement including fees		$ 5,000,000
Debt Instrument, Payment Terms						On October 18, 2019, the Company entered into an amendment to the 2nd A&R Loan Agreement with the Lenders. Pursuant to the amendment, the Company repaid $5.0 million of the outstanding principal balance of the $10.0 million term loan. The Company did not pay any final payment or termination fees in connection with the $5.0 million prepayment. In addition, the Company and the Lenders agreed to modify the term loan repayment schedule. As amended, the term loan repayment schedule provided for interest only payments through October 31, 2020, followed by consecutive equal monthly payments of principal and interest in arrears continuing through the maturity date of October 1, 2022.
Loans held-for-sale, maturity date		Oct. 1, 2022
Debt instrument, principal balance payment	$ 5,000,000
Debt Instrument, Final Payment, Interest	$ 300,000
Silicon Valley Bank, MidCap Funding III Trust and MidCap Financial Trust | Second Amended and Restated Loan and Security Agreement
Debt Instrument [Line Items]
Fixed interest rate			6.50%
Variable interest rate			1.89%
Debt instrument, description of variable rate basis						30-day U.S. LIBOR
Line of credit facility, maximum borrowing capacity			$ 20,000,000
Long term debt			10,000,000
Line of credit facility, remaining borrowing capacity description						Of the remaining $10.0 million under the 2nd A&R Loan Agreement, the Company elected not to draw $5.0 million and the other $5.0 million was not available for draw.
Line of credit facility remaining borrowing capacity not available for withdraw			5,000,000
Line of credit facility, remaining borrowing capacity			5,000,000
Silicon Valley Bank, MidCap Funding III Trust and MidCap Financial Trust | Second Amended and Restated Loan and Security Agreement, Initial Tranche
Debt Instrument [Line Items]
Long term debt			10,000,000
Silicon Valley Bank , MidCap Funding XII Trust and MidCap Financial Trust | First Amended and Restated Loan and Security Agreement | Final Payment
Debt Instrument [Line Items]
Repayment of outstanding amount under the loan agreement including fees			$ 7,000,000

CARES Act Paycheck Protection_2

CARES Act Paycheck Protection Program Loan - Additional Information (Details) - PPP Loan - USD ($) $ in Millions	1 Months Ended
	Apr. 20, 2020	Sep. 30, 2020
Short Term Debt [Line Items]
Short-term Debt		$ 0.6
Long term debt		$ 0.4
Silicon Valley Bank
Short Term Debt [Line Items]
Aggregate principal amount	$ 1
Interest rate on outstanding principal amount	1.00%
Note, Maturity date	Apr. 30, 2022
Silicon Valley Bank | Minimum
Short Term Debt [Line Items]
Eligible Payroll Costs	60.00%

Common Stock - Additional Infor

Common Stock - Additional Information (Details) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Common stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares outstanding	48,227,442	44,413,372

Stock Purchase Warrants - Addit

Stock Purchase Warrants - Additional Information (Details) - Convertible Stock Warrant - $ / shares	1 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2020
Class Of Warrant Or Right [Line Items]
Class of warrant Exercise	$ 10.74
Warrants expiration term	2026-09
Weighted average remaining life of warrants		6 years
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Number of stock that can be purchased by each warrant	29,796

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Share-based Compensation Expense (Details) - Stock Options - 2011 Stock Incentive Plan, 2016 Equity Incentive Plan - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 674	$ 786	$ 2,057	$ 3,232
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	290	243	881	1,066
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 384	$ 543	$ 1,176	$ 2,166

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Activity Related to Stock Options (Details) - Stock Options	9 Months Ended
	Sep. 30, 2020$ / sharesshares	Dec. 31, 2019$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Options outstanding, Beginning balance | shares	4,104,450
Number of Shares, Granted | shares	1,100,250
Number of Shares, Exercised | shares	(253,216)
Number of Shares, Forfeited | shares	(702,041)
Number of Shares, Options outstanding, Ending balance | shares	4,249,443
Number of Shares, Options exercisable | shares	2,225,536	2,452,764
Weighted Average Exercise Price, Options outstanding, Beginning balance | $ / shares	$ 4.63
Weighted Average Exercise Price, Granted | $ / shares	2.31
Weighted Average Exercise Price, Exercised | $ / shares	0.89
Weighted Average Exercise Price, Forfeited | $ / shares	6.49
Weighted Average Exercise Price, Options outstanding, Ending balance | $ / shares	3.95
Weighted Average Exercise Price, Options exercisable | $ / shares	$ 4.97	$ 5.44

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Two Thousand Sixteen Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 17,000	$ 2,000	$ 24,000	$ 15,000
Issuance of common shares underemployee stock purchase plan			35,359
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to unvested stock options	4,100,000		$ 4,100,000
Expected to be recognized over a weighted average period			2 years 3 months 18 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected to be recognized over a weighted average period			2 years 7 months 6 days
Share-based compensation expense	200,000	$ 45,000	$ 700,000	$ 0.2
Unrecognized compensation expense related to the RSUs	$ 1,200,000		$ 1,200,000

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of the Activity Related to RSUs (Details) - Restricted Stock Units (RSUs)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested units outstanding, Number of Shares, Beginning balance | shares	1,269,300
Number of Shares, Granted | shares	486,000
Number of Shares, Vested | shares	(887,575)
Number of Shares, Forfeited | shares	(6,700)
Non-vested units outstanding, Number of Shares, Ending balance | shares	861,025
Non-vested units outstanding, Weighted Average Exercise Price, Beginning balance | $ / shares	$ 0.87
Weighted Average Exercise Price, Granted | $ / shares	2.39
Weighted Average Exercise Price, Vested | $ / shares	0.93
Weighted Average Exercise Price, Forfeited | $ / shares	0.91
Non-vested units outstanding, Weighted Average Exercise Price, Ending balance | $ / shares	$ 1.67

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 30, 2016USD ($)ft²	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)
Commitment And Contingencies [Line Items]
Lessee, operating lease, option to extend, description				The renewal option is not included in the calculation of the right-of-use asset and the lease liabilities as the Company has not yet determined if the Alpharetta, Georgia lease will be renewed.
Incremental borrowing rate		11.00%		11.00%
Operating lease, remaining lease term		3 years		3 years
Operating Lease, Cost		$ 62,000	$ 100,000	$ 185,000	$ 300,000
Variable Lease, Cost		24,000	36,000	71,000	122,000
Short-term Lease, Cost		$ 2,000	$ 4,000	10,000	13,000
Cash payments included in operating activities for operating lease liabilities				$ 283,000	$ 389,000
GEORGIA
Commitment And Contingencies [Line Items]
Area of office leased | ft²	20,000
Operating lease agreement term	6 years 6 months
Operating lease agreement renewal option term	5 years
Minimum monthly lease payments	$ 35,145
Percentage of increase per year	3.00%

Commitment and Contingencies _2

Commitment and Contingencies - Operating Leases Included on the Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Operating lease right-of-use asset	$ 563	$ 656
Liabilities
Current portion of operating lease liabilities	370	360
Operating lease liabilities	689	$ 897
Total operating lease liabilities	$ 1,059

Commitment and Contingencies _3

Commitment and Contingencies - Future Minimum Commitments Due Under Non-Cancelable Operating Leases (Details) $ in Thousands	Sep. 30, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
2020	$ 95
2021	392
2022	407
2023	316
Total minimum lease payments	1,210
Less imputed interest	(151)
Total operating lease liabilities	$ 1,059

License and Other Agreements -

License and Other Agreements - Additional Information (Detail) - USD ($)	Apr. 27, 2020	Mar. 10, 2020	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Research And Development Arrangement Contract To Perform For Others [Line Items]
License and other revenue			$ 3,432,000		$ 141,000	$ 7,883,000	$ 231,000
Other Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
License and other revenue			$ 0		$ 15,000	$ 200,000	$ 0.1
Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Other short-term collaboration agreements performance obligations period				2 months
Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Other short-term collaboration agreements performance obligations period				1 month
Bausch Health Ireland Limited
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment	$ 5,000,000
First cumulative net sales of products	45,000,000
Bausch Health Ireland Limited | Commercial Arrangement | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Pre-launch milestone payments	15,000,000
Additional milestone payments	$ 57,300,000
Arctic Vision Limited
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment				$ 4,000,000
Amount of upfront payment and development milestones payment to be received under license agreement		$ 35,500,000
Arctic Vision Limited | Upfront Payment
Research And Development Arrangement Contract To Perform For Others [Line Items]
License and other revenue				$ 4,000,000
Arctic Vision Limited | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development milestone payments		$ 31,500,000
Threshold percentage of sales for tiered royalties		12.00%
Arctic Vision Limited | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Threshold percentage of sales for tiered royalties		10.00%

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Significant transfers between Levels 1, 2 and 3	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets Measured at Fair Value (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Financial Assets:
Total financial assets	$ 15,199	$ 22,955
Level 1
Financial Assets:
Total financial assets	15,199	22,955
Cash and Money Markets
Financial Assets:
Total financial assets	14,839	22,595
Cash and Money Markets | Level 1
Financial Assets:
Total financial assets	14,839	22,595
Restricted Cash Money Market
Financial Assets:
Total financial assets	360	360
Restricted Cash Money Market | Level 1
Financial Assets:
Total financial assets	$ 360	$ 360

Net Loss Per Share - Potential

Net Loss Per Share - Potential Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	5,140,264	5,541,980	5,140,264	5,541,980
Outstanding Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	4,249,443	4,192,884	4,249,443	4,192,884
Non-vested Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	861,025	1,319,300	861,025	1,319,300
Stock Purchase Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	29,796	29,796	29,796	29,796